FDA Approves Ilumya for Psoriatic Arthritis

FDA approved a new indication for Ilumya (tildrakizumab-asmn) on 30 October 2026, adding active psoriatic arthritis in adults to a label that has covered moderate-to-severe plaque psoriasis since 2018. Sun Pharmaceutical Industries' supplemental Biologics License Application rested on two Phase 3 trials, both meeting their primary endpoint against placebo.

What the approval adds

Tildrakizumab-asmn is a monoclonal antibody that selectively binds the p19 subunit of interleukin-23 (IL-23), blocking a cytokine pathway implicated in both plaque psoriasis and psoriatic arthritis. FDA first approved Ilumya in 2018 for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and Sun Pharma has incrementally expanded the label since — scalp psoriasis in April 2024, nail psoriasis in December 2025, and now active psoriatic arthritis. The new indication puts Ilumya alongside other IL-23-class biologics already approved for psoriatic arthritis, expanding the treatment options available to rheumatologists and dermatologists managing patients with overlapping skin and joint disease.

The INSPIRE trials

The approval rests on INSPIRE-1 and INSPIRE-2, a pair of Phase 3, multicenter, randomized, double-blind, placebo-controlled studies, each running 52 weeks and dosing tildrakizumab at 100 mg. The two trials were designed to cover different prior-treatment populations: INSPIRE-1 enrolled patients with prior exposure to anti-TNF therapy, a group that often represents a harder-to-treat population after an inadequate response or intolerance to a first-line biologic, while INSPIRE-2 enrolled patients naive to anti-TNF therapy. Both trials showed statistically significant superiority over placebo on the primary efficacy endpoint, ACR20 response — at least a 20% improvement in American College of Rheumatology composite disease-activity criteria — at 24 weeks. Running the two trials in parallel across anti-TNF-experienced and -naive populations lets the label speak to psoriatic arthritis patients regardless of where they sit in the typical treatment sequence, rather than requiring a narrower, treatment-history-restricted indication.

A crowded class, with one administration difference

Ilumya enters psoriatic arthritis as one of several approved IL-23-pathway inhibitors in the indication; Regulatory News has not independently verified a specific numbered ranking (such as being the "third" IL-23 inhibitor approved for the condition) and does not assert one here. What is verifiable from the label itself is an administration difference Sun Pharma has emphasized in its own announcement: Ilumya is approved exclusively for healthcare-provider administration, unlike other biologics in its class that offer a self-administered pen or prefilled syringe for at-home use. That distinction shifts where and how often patients interact with the healthcare system for dosing — a practical consideration for site-of-care planning and payer coverage discussions, separate from the comparative efficacy data itself.

What RA/QA and clinical-operations teams should note

• Administration setting changes site-of-care logistics. A provider-administered-only biologic requires infusion-center or clinic capacity rather than patient self-injection at home — relevant for practices and health systems planning capacity around a new psoriatic arthritis treatment option.
• Safety profile carries over, with watch items consistent across indications. Upper respiratory tract infections and COVID-19 were the most common adverse reactions (≥3%) in the psoriatic arthritis trials, tracking Ilumya's established psoriasis safety profile rather than introducing a new signal specific to the joint-disease population.
• This is Sun Pharma's fourth label expansion for the molecule since 2018 (psoriasis, scalp psoriasis, nail psoriasis, now psoriatic arthritis) — a pattern of sequential supplemental filings on a single approved biologic that RA/QA teams tracking competitor lifecycle strategy may find instructive for their own post-approval expansion planning.

Frequently asked questions

What did FDA approve on 30 October 2026?

A supplemental BLA for Ilumya (tildrakizumab-asmn), adding active psoriatic arthritis in adults to its existing plaque-psoriasis indication.

What evidence supported the approval?

Two Phase 3 trials, INSPIRE-1 (anti-TNF-experienced patients) and INSPIRE-2 (anti-TNF-naive patients), both 52-week, randomized, double-blind, placebo-controlled studies that met the primary endpoint of ACR20 response at 24 weeks.

How is Ilumya administered, and how is that different from competitors?

Exclusively by a healthcare provider, not through patient self-injection — a distinction Sun Pharma markets as differentiating it from other IL-23-class biologics offering home self-administration.

What were the most common side effects in the psoriatic arthritis trials?

Upper respiratory tract infections and COVID-19, each in at least 3% of patients, consistent with the safety profile from Ilumya's existing psoriasis indications.